Liver-directed gene therapy with lentiviral vectors achieve normal levels of clotting factor VIII and IX in non-human primates

被引：0
|
作者：
Milani, M. [1 ]
Canepari, C. [1 ]
Annoni, A. [1 ]
Liu, T. [3 ]
Plati, T. [1 ]
Biffi, M. [1 ]
Russo, F. [1 ]
Patarroyo-White, S. [3 ]
Drager, D. [3 ]
Ayuso, E. [4 ]
Peters, R. [3 ]
Naldini, L. [1 ,2 ]
Cantore, A. [1 ,2 ]
机构：
[1] San Raffaele Telethon Inst Gene Therapy HSR TIGET, Milan, Italy
[2] Vita Salute San Raffaele Univ, Milan, Italy
[3] Sanofi, Paris, France
[4] Univ Nantes, INSERM, UMR 1089, Nantes, France
来源：
HUMAN GENE THERAPY | 2019年 / 30卷 / 11期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
P201
引用
收藏
页码：A77 / A77
页数：1
相关论文
共 50 条
  • [21] Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver
    Park, F
    Ohashi, K
    Kay, MA
    BLOOD, 2000, 96 (03) : 1173 - 1176
  • [22] Neutralizing Antibody Affects Liver-Mediated Factor IX Expression in Non-Human Primates by AAV Vectors
    Mizukami, Hiroaki
    Mimuro, Jun
    Ishiwata, Akira
    Ono, Fumiko
    Yagi, Hiroya
    Urabe, Masashi
    Kume, Akihiro
    Terao, Keiji
    Yasutomi, Yasuhiro
    Sakata, Yoichi
    Ozawa, Keiya
    MOLECULAR THERAPY, 2009, 17 : S314 - S315
  • [23] In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles
    Dissen, Gregory A.
    Lomniczi, Alejandro
    Neff, Tanaya L.
    Hobbs, Theodore R.
    Kohama, Steven G.
    Kroenke, Christopher D.
    Galimi, Francesco
    Ojeda, Sergio R.
    METHODS, 2009, 49 (01) : 70 - 77
  • [24] Shielding lentiviral vectors from phagocytosis increases hepatocyte gene transfer in non-human primates
    Cantore, A.
    HUMAN GENE THERAPY, 2018, 29 (12) : A30 - A30
  • [25] Lentiviral vectors designed for liver-directed gene therapy do not display detectable genotoxicity in sensitive in vivo assays
    Ranzani, Marco
    Cantore, Alessio
    Volpin, Monica
    Sanvito, Francesca
    Gallina, Pierangela
    Bartholomae, Cynthia
    Benedicenti, Fabrizio
    Annunziato, Stefano
    Sergi, Lucia Sergi
    von Kalle, Christof
    Doglioni, Claudio
    Schmidt, Manfred
    Naldini, Luigi
    Montini, Eugenio
    HUMAN GENE THERAPY, 2012, 23 (10) : A38 - A38
  • [26] Relationship between neutralizing antibody and liver-mediated factor IX expression in non-human primates using AAV vectors
    Mizukami, Hiroaki
    Mimuro, Jun
    Ishiwata, Akira
    Ono, Fumiko
    Yagi, Hiroya
    Urabe, Masashi
    Kume, Akihiro
    Terao, Keiji
    Yasutomi, Yasuhiro
    Sakata, Yoichi
    Ozawa, Keiya
    HUMAN GENE THERAPY, 2009, 20 (11) : 1481 - 1482
  • [27] Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
    Samelson-Jones, Benjamin J.
    Arruda, Valder R.
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [28] AAV-mediated liver-directed gene therapy for the hemophilias: doses, factor levels and the human immune response
    High, K. A.
    HUMAN GENE THERAPY, 2016, 27 (11) : A16 - A16
  • [29] Developing and Evaluating Second-Generation AAV Vectors for Liver-Directed Gene Therapy of Familial Hypercholesterolemia in Nonhuman Primates
    Wang, Lili
    Wang, Qiang
    Muthuramu, Ilayaraja
    Bell, Peter
    Chichester, Jessica A.
    Somanathan, Suryanarayan
    Zhang, Hong
    He, Zhenning
    Ying, Lei
    Tretiakova, Anna
    Wilson, James M.
    MOLECULAR THERAPY, 2020, 28 (04) : 578 - 579
  • [30] Lentiviral Vectors Tailored for Liver-Directed Gene Therapy Do Not Show Any Detectable Genotoxicity in Sensitive In Vivo Biosafety Assays
    Ranzani, Marco
    Cantore, Alessio
    Volpin, Monica
    Gallina, Pierangela
    Annuziato, Stefano
    Sanvito, Francesca
    Benedicenti, Fabrizio
    Bartholomae, Cynthia
    Sergi, Lucia Sergi
    von Kalle, Christof
    Schmidt, Manfred
    Doglioni, Claudio
    Naldini, Luigi
    Montini, Eugenio
    MOLECULAR THERAPY, 2013, 21 : S254 - S255
12345